Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Phase of Trial: Phase IV
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Bimatoprost (Primary) ; Timolol; Travoprost
- Indications Glaucoma; Ocular hypertension
- Focus Therapeutic Use
- Sponsors Allergan
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.